The buyback execution is too small to move the stock. Monitor future filings under the same program for cumulative repurchase volume that could signal directional conviction from management. The cross-filed 20-F annual report provides context on the company's operational and financial position — review that for fundamental trading cues rather than this routine buyback disclosure.
Price Chart
Executive Summary
Lakefront Biotherapeutics disclosed the repurchase of 38,537 ordinary shares at a total cost of approximately €954,809 under a buyback program announced June 9, 2026. The repurchases occurred on the Euronext exchange between June 10-12, 2026 at an average price of €24.78 per share. This is a routine capital allocation update with no material financial impact relative to the company's $1.9B market cap.
Key Facts
- 38,537 shares repurchased between June 9-12, 2026 under a program announced June 9, 2026
- Total cost: approximately €954,809
- Average price paid: approximately €24.78 per share
- Repurchases executed exclusively on the ENXT (Euronext Brussels) market
- As of June 12, 2026, Lakefront holds 38,537 of its own ordinary shares
- The repurchase program was announced on June 9, 2026 (referenced but not detailed in this filing)
Financial Impact
Approximately €954,809 spent on share repurchases — equivalent to less than 0.1% of the $1.9B market cap. Immaterial.
Risk Factors
- No insight into total authorized repurchase size or program duration from this filing alone
- Small repurchase scale suggests no aggressive buyback conviction; may disappoint investors expecting meaningful capital return
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004149 |
| Document: f6k_061626.htm | 0001171843-26-004149 |
| Document: 0001171843-26-004149-index-headers.html | 0001171843-26-004149 |
| Document: 0001171843-26-004149-index.html | 0001171843-26-004149 |
| Document: 0001171843-26-004149.txt | 0001171843-26-004149 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $30.58 | awaiting T+20 | — | $31.69 (+3.63%) |
Oct 14, 2026 12d ago | 6-K | $29.93 | awaiting T+20 | — | $31.69 (+5.88%) |
Oct 13, 2026 13d ago | 6-K | $29.40 | awaiting T+20 | — | $31.69 (+7.79%) |
Oct 6, 2026 20d ago | 6-K | $30.00 | awaiting T+20 | — | $31.69 (+5.63%) |
Sep 1, 2026 7w ago | 6-K | $28.81 $29.65 | ▲ +2.92% | ▲ +3.25% | $31.69 (+10.00%) |
Aug 25, 2026 8w ago | 6-K | $29.70 $30.72 | ▲ +3.43% | ▲ +2.46% | $31.69 (+6.70%) |
Aug 12, 2026 10w ago | 6-K | $27.93 $26.81 | ▼ −4.01% | ▼ −2.11% | $31.69 (+13.46%) |
Jul 28, 2026 12w ago | 6-K | $27.72 $29.16 | ▲ +5.19% | ▲ +0.17% | $31.69 (+14.32%) |
Jun 30, 2026 16w ago | 6-K | $29.60 $27.72 | ▼ −6.35% | ▼ −4.17% | $31.69 (+7.06%) |
Jun 24, 2026 17w ago | 6-K | $29.01 $28.78 | ▼ −0.79% | ▼ −2.73% | $31.69 (+9.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers